Background
Myasthenia gravis (MG) is a T cell-dependent and antibody-mediated autoimmune disease characterized with fluctuating muscle weakness due to neuromuscular junction (NMJ) dysfunction mostly induced by acetylcholine receptor (AChR) antibodies [
1]. MG is currently treated with global immunosuppressants with substantial side effects including steroids, azathioprine, and other cytotoxic drugs. Around 5–10 % of MG patients display muscle-specific tyrosine kinase (MuSK) antibodies. MuSK antibody-positive MG patients often present with a severe clinical course and higher dosages of immunosuppressants are required for their management [
2], prompting the innovation of novel therapeutic reagents with specific mechanisms of action and fewer side effects.
Mesenchymal stem cells (MSCs) are multipotent adult stem cells. They have been isolated from various sources, such as cord blood, Wharton’s jelly, the placenta, bone marrow, teeth, and adipose tissue [
3‐
11].
A promising source of MSCs is dental tissue, which is easily accessible and can be isolated from many sources of the orofacial region, such as stem cells isolated from human exfoliated deciduous teeth (SHEDs), dental pulp stem cells (DPSCs), dental follicle stem cells (DFSCs), and periodontal ligament stem cells (PDLSCs) [
11‐
14]. MSCs show expression of embryonic stem cell markers Oct4, NANOG, SOX2, alkaline phosphatase, and SSEA-4 in adult MSC populations derived from the bone marrow, adipose tissue, dermis, and heart [
9‐
14].
As a promising therapeutic tool to suppress inflammation and immunomodulation, MSCs have been widely used in preclinical treatment studies of several autoimmune disorders [
15‐
21]. Recently, MSCs from bone marrow have been successfully employed in AChR-induced experimental autoimmune myasthenia gravis (EAMG) model resulting in amelioration of muscle weakness and reduction of AChR-reactive lymphocytes [
21]. However, in this previous study, immunopathogenic aspects of EAMG have not been comprehensively investigated.
In this study, the efficacy of stem cell treatment has been tested in MuSK-associated EAMG for the first time and immunopathogenic features of MSC-treated mice have been analyzed. Our results suggest that MSC administration might constitute a specific and effective treatment method in MuSK-associated MG.
Methods
Mice and MuSK
Seven- to 8-week-old wild-type C57BL/6 (B6) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). All animals were housed in the viral antibody-free barrier facility at the Istanbul University and maintained according to the Institutional Animal Care and Use Committee Guidelines. The extracellular domain of human MuSK (amino acids 1–463, MUSK_HUMAN O15146-3) was cloned into the pPICZαA vector (Invitrogen, San Diego, CA, USA) and was expressed in Pichia pastoris host strain X33 as soluble protein in the yeast culture supernatant as described previously [
22,
23]. The expressed protein was purified by metal affinity chromatography using Ni-NTA agarose resin (Qiagen, Valencia, CA, USA), according to the manufacturer’s protocol. The purity of the protein was documented by gel electrophoresis and western blotting with a commercial anti-human MuSK antibody (Abcam, Cambridge, UK).
Isolation of dental follicle MSC (DFMSC)
Dental follicles (DF) were collected from the Marmara University Faculty of Dentistry Oral and Maxillofacial Surgery. The legitimate delegate of all patients provided informed consent according to the guidelines of the Ethics Committee of the Marmara University Medical Faculty in Istanbul, Turkey (09.2014.0015/70737436-050.06.04). These follicles were transported in Dulbecco’s phosphate-buffered saline (DPBS, Gibco, Grand Island, NY 14072, USA) containing 1 % penicillin/streptomycin (Gibco, USA). All laboratory work was performed in a laboratory in the Department of Pediatric Allergy-Immunology, Marmara University Research Hospital.
Follicles were isolated under sterile conditions. They were enzymatically treated with 3 mg/ml collagenase type I (Gibco, USA) for 45 min at 37 °C to completely digest pulp and follicle tissue. Then, 3 ml of Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) supplemented with 10 % fetal bovine serum (FBS, Gibco, USA) and 1 % penicillin/streptomycin was added to digest the pulp and follicle tissue followed by centrifugation at 1200 rpm for 5 min. Cell pellets were obtained, and the supernatant was aspirated. DFMSCs were cultivated in T-25 flasks in a 5 % CO2 atmosphere under 37 °C in culture medium composed of DMEM, 10 % FBS, and 1 % penicillin/streptomycin. The stem cells were washed with DPBS and provided with fresh culture medium. The culture medium was changed every 3 to 4 days until the cells reached confluence. The cells were detached with 0.25 % trypsin-EDTA (Gibco, USA) when they reached 70–80 % confluence. Adherent cells cultured for 3 passages were characterized and analyzed for specific surface markers. The cellular analyses and differentiation were performed using flow cytometry.
Flow cytometry analysis of DFMSCs
To analyze the cell surface antigen expressions, the cells from the third passage were used. DFMSCs were incubated with antibodies for human CD73 phycoerythrin (PE), CD90 PE, CD146 fluorescein isothiocyanate (FITC), CD29 allophycocyanin (APC), CD105 PE, CD45 FITC, CD34 PE, CD14 PE, CD25 APC, and CD28 PE (BD Biosciences, San Diego, CA, USA) at room temperature in the dark. Control antibodies were PE-conjugated or FITC-conjugated and APC-conjugated mouse IgG1 and mouse IgG2 (BD Biosciences, San Diego, CA, USA). The flow cytometry results were analyzed using BD FACS Calibur.
Differentiation of stem cells
To induce osteogenic (MesenCult, Stemcell Technologies, North America), adipogenic, and chondrogenic differentiation, a human MSC functional identification kit (Gibco, Grand Island, USA) was used. For differentiation, the cells were plated in 6-well plates (5 × 10
4 cell/well), and the differentiation medium was prepared according to the manufacturer’s instructions and changed 3 times per week. After 14 days, the adipocytes and chondrocytes were stained with Oil Red O and Alcian blue, respectively, and after 28 days, the osteocytes were stained with Alizarin red [
24].
Real-time PCR analysis
Total RNA was isolated from 1 × 106 DFMSCs at passage 3 using a high pure RNA isolation kit (Roche, Mannheim, Germany) according to the manufacturer’s instructions. One microgram of total RNA was converted to cDNA using a Transcriptor first-strand cDNA synthesis kit (Roche Mannheim, Germany). Equal amounts of cDNA were used for the real-time amplification of the target genes according to the manufacturer’s recommendations using a LightCycler 480 Real-Time PCR System (Roche Diagnostic, Mannheim, Germany). The gene expression of specific markers for MSCs, including alkaline phosphatase (ALPL), runt-related transcription factor 2 (RUNX2), NANOG, NESTİN, NOTCH, and dentin sialophosphoprotein (DSPP), was quantified relative to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The RT-PCR conditions were as follows: pre-incubation for 10 min at 95 °C for 1 cycle; amplification for 10 s at 95 °C, 60 °C for 30 s, 72 °C for 1 s for 45 cycles; and cooling for 10 s at 40 °C for 1 cycle. The reaction mixture lacking cDNA was used as a negative control in each run. The real-time PCR results were analyzed using LightCycler software (version 2).
Induction and clinical evaluation of EAMG
A total of 20 B6 mice were anesthetized and immunized with 30 μg of MuSK emulsified in complete Freund’s adjuvant (CFA, Difco, Detroit, MI, USA) s.c. at four sites (two hind footpads and shoulders) on day 0 and were boosted with the same amount of MuSK in CFA s.c. at four sites on the back on days 28 and 56. An additional 20 control mice were immunized with only CFA. The number of cells to be administered per injection was determined during optimization studies. During these studies, clinical results obtained with mouse compact bone MSC and DFMSC treatments were also compared (Additional file
1: Table S1). The DFMSCs were freshly prepared before each injection. They were trypsinized and washed for two times with PBS, and 1 × 10
6 DFMSCs were administered intravenously in 1 h via an insulin syringe from the tail vein twice (7 days after second and third immunizations) to MuSK + CFA (MuSK-SC,
n = 10) and only CFA (CFA-SC,
n = 10) -immunized mice. The remaining mice from MuSK + CFA (
n = 10) and only CFA (n = 10) groups were used as non-DFMSC treatment controls and were treated with PBS only. Mice were terminated 28 days after the third immunization.
For clinical examination, mice were left for 3 min on a flat platform and were observed for signs of EAMG. Clinical muscle weakness was graded as follows: grade 0, mouse with normal posture, muscle strength, and mobility; grade 1, normal at rest, with muscle weakness characteristically shown by a hunched posture, restricted mobility and difficulty raising the head after exercise that consisted of 30 paw grips on a cage top grid; grade 2, grade 1 symptoms without exercise during the observation period on a flat platform; grade 3, dehydrated and moribund with grade 2 weakness; and grade 4, dead.
Inverted screen test was administered for quantitative evaluation of muscle weakness. Mice were placed in the center of a screen of wire mesh, which was immediately rotated to the inverted position and held steadily 50 cm above a padded surface. The time at which the mouse fell off was noted with an endpoint of 300 s. The recorded time was compared for statistical significance among treatment and control groups.
ELISA for anti-MuSK Ig isotypes
Mice were bled from the tail vein during termination. Sera were evaluated for anti-MuSK IgG, IgG1, IgG2b, IgG3, and IgM levels. Affinity-purified human MuSK (1 μg/ml) was coated onto 96-well microtiter plates in 0.1 M carbonate bicarbonate buffer overnight at 4 °C. Diluted serum samples of 100 μl (1:1000) were added and incubated at 37 °C for 90 min. Horseradish peroxidase (HRP)-conjugated anti-mouse IgG, IgG1, IgG2b, IgG3, and IgM (Abcam) (1:10,000) were added and then incubated at 37 °C for 90 min. Subsequently, the peroxidase indicator substrate 2,2′-azinobis-(3-ethylbenzothiazoline 6-sulfonate) substrate (ABTS) solution in 0.1 M citric buffer (pH 4.35) was added in the presence of H2O2, and the mixture was allowed to develop color at room temperature in the dark. Plates were read at a wavelength of 405 nm.
Immunofluorescence for NMJ IgG and C3 deposits
Sections (10 μm thick) were obtained from forelimb muscle samples of mice, frozen in liquid nitrogen, and stored at −80 °C. Slides were fixed in cold acetone and blocked in 10 % normal goat serum in PBS. After washing with PBS, the sections were incubated with tetramethylrhodamine-conjugated bungarotoxin (BTx) (Molecular Probes, Eugene, OR) (1/500 dilution) for 1 h at room temperature to label the NMJ. Sections were then incubated for 1 h at room temperature with FITC-conjugated antibodies to mouse IgG or complement factor C3 (Abcam) (diluted 1/1000) to colocalize IgG and C3 deposits in NMJ. The sections were washed and viewed in a fluorescence microscope (Olympus IX-70). The number of IgG- and C3-positive BTx binding sites was counted in five muscle sections from each mouse. The percentages of NMJs with deposits in each muscle section were calculated by totaling the numbers of deposits divided by the numbers of BTx-labeled sites, times 100.
Flow cytometry for lymph node cell subpopulations
In immunization-based EAMG models, antigens are injected subcutaneously to body parts that are in close proximity with the lymph nodes. As a result, immunopathogenic processes leading to antibody formation and muscle weakness predominantly occur in the local draining lymph nodes. Therefore, in our study, all immunopathological studies were conducted using lymph node cells. For this purpose, inguinal, popliteal, and axillary lymph node cells were collected at the termination of the experiment. Single-cell suspensions of lymph node cells were incubated for 30 min with one of the following anti-mouse antibodies: PE-conjugated anti-CD4, anti-CD19, anti-CD11b, and anti-CD3 and FITC-conjugated anti-CD8 (all from BD PharMingen). PE- or FITC-conjugated isotypes were used for controls. Cells were washed twice and then were fixed with 2 % paraformaldehyde and analyzed by flow cytometry (BD Biosciences).
Lymphocyte proliferation assay
The percentage of proliferating cells in response to MuSK stimulation was measured by carboxyfluorescein succinimidyl ester (CFSE) labeling. Lymph node cells (6 × 105 cells/well) were seeded in triplicate into 48-well plates in 0.5 ml of culture medium [RPMI 1640 supplemented with 10 % fetal calf serum, penicillin G (100 U/ml) streptomycin (100 μg/ml), L-glutamine (2 mM), 2-mercaptoethanol (3 × 10−5 M) and HEPES buffer (25 mM)] in the absence or presence (5 or 15 μg) of MuSK. After being cultured for 4 days at 37 °C in humidified 5 % CO2-enriched air, cells were labeled with CFSE-FITC (5 μmol/L; Molecular Probes Europe, BV, Leiden, The Netherlands) and analyzed by flow cytometry (BD Biosciences).
Cytokine measurements in culture supernatants
Lymph node cells (2 × 105 cells/well) were seeded in triplicate into 96-well, round-bottomed microtiter plates in 0.2 ml of culture medium in the absence or presence (5 or 15 μg) of MuSK. The cells were cultured for 48 h at 37 °C in humidified 5 % CO2-enriched air. Supernatants were collected and stored at −80 °C until analyzed. The supernatant levels of IL-4, IL-10, IL-13, IFN-γ, IL-12, IL-21, IL-17, IL-6, TGF-β, and TNF-α were measured by ELISA kits (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions.
Statistical analysis
Clinical EAMG incidences were compared using the Fisher’s exact test. Clinical grades were compared by Kruskal–Wallis test and Dunn’s post hoc test. All other parameters were compared using ANOVA (and Tukey’s post hoc test). p values less than 0.05 were considered statistically significant.
Discussion
MSC administration has previously been shown to reduce clinical severity, serum antibody levels, and lymphocyte proliferation in the EAMG model induced by AChR immunization [
21]. In this study, we have shown for the first time that DFMSC administration also ameliorates clinical and basic immunopathological findings of EAMG induced by MuSK immunization. In consistency with the previous report, DFMSC-treated mice did not only have lower clinical scores than untreated mice, but they also exhibited reduced anti-MuSK IgG levels, NMJ deposits, and lymph node cell proliferation capacity in response to MuSK stimulation. In line with EAMG studies, a single patient with AChR antibody-positive MG and motor neuronopathy has benefited from autologous bone marrow-derived MSC treatment [
25], corroborating the notion that MSC may be effectively used as a potential future treatment method for MG patients.
In addition to previous EAMG studies, our studies also suggest that MSCs exert their beneficial effects presumably through suppression of CD11b+ cells. This marker is predominantly expressed by cells from the myeloid lineage and innate immune system displaying functions such as phagocytosis, antigen presentation, and neutrophil aggregation [
26‐
29]. In the lymph node, CD11b is expressed by dendritic cells [
27,
29,
30], which are known to play a crucial role in EAMG pathogenesis through presentation of NMJ antigens to lymphocytes and consequent activation of self-reactive T and B cells [
31]. Therefore, as expected, treatment methods based on suppression of dendritic cell functions have effectively inhibited EAMG development in experimental models [
31,
32]. Fcγ receptor knockout mice exhibiting impaired dendritic cell phagocytosis functions are known to be resistant to EAMG induction [
33]. Moreover, DFMSCs have previously been shown in different animal models to preferentially inhibit cytokine secretion by dendritic cells and alter dendritic cell functions [
34,
35]. It is thus tempting to speculate that DFMSC treatment ameliorates myasthenic muscle weakness through suppression of CD11b+ dendritic cells. However, CD11b is also expressed by monocytes, granulocytes, macrophages, and natural killer cells [
26‐
29], all of which might potentially participate in EAMG pathogenesis. Therefore, exact significance of CD11b+ cell suppression and distinct cell populations involved in DFMSC-mediated EAMG amelioration need to be further studied through screening of an extensive panel of innate immunity markers by flow cytometry methods.
Notably, in our study, production of several cytokines primarily secreted by T and B cells were unaffected by DFMSC treatment. By contrast, the only two cytokines (IL-6 and IL-12) that were suppressed by DFMSC treatment are predominantly produced by myeloid cell lineage [
36,
37]. Both IL-6 and IL-12 knockout mice have been shown to display significant resistance to EAMG induced by AChR immunization. Moreover, in resemblance to DFMSC-treated mice, both knockout mouse strains showed reduced antibody production, NMJ deposits, and lymphocyte proliferation capacity following EAMG induction [
38,
39]. Although the significance of these two cytokines in MuSK-related MG is not well known, treatment methods based on IL-6 and IL-12 inhibition might presumably prove beneficial for MuSK antibody-positive MG patients, as well. Notably, despite exhibiting increased IL-4 and IL-10 levels as compared to CFA-immunized mice (as reported previously [
40]), DFMSC-treated mice showed lower EAMG severity than non-DFMSC-treated mice, implying that non-Th2-type innate immunity also participates in MuSK-associated EAMG. Therefore, combined inhibition of Th2 immunity and the innate immune system might be required for effective treatment of MuSK antibody-positive MG patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CU designed the study, performed immunization studies, analyzed the data, and drafted the manuscript. NZ and SY prepared stem cells, isolated PBMCs, and carried out flow cytometry and culture studies. NT and PZ purified the MuSK protein and performed the assays for verification of MuSK. MK and HT performed immunization studies, provided tissue sections, and carried out immunohistochemistry. ST participated in MuSK purification, designed the study, and helped draft the manuscript. KG provided surgical specimens for stem cells and helped draft the manuscript. ET and TA designed the study, analyzed the data, and drafted the manuscript. All authors read and approved the final manuscript.